Opus Genetics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Opus Genetics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $484.00K.
- Opus Genetics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $738.00K, a 14660.00% increase year-over-year.
- Opus Genetics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $22.00K.
- Opus Genetics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $5.00K.
- Opus Genetics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $352.00K.
- Opus Genetics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $30.00K, a 11.11% increase from fiscal 2022.
- Opus Genetics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $27.00K, a 68.97% decline from fiscal 2021.
- Opus Genetics, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $87.00K, a 50.00% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $484.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $738.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $352.00K 10-K · filed 2026-03-12 | |
| 2025-09-30 | $22.00K 10-Q · filed 2025-11-12 | |
| 2025-03-31 | $5.00K 10-Q · filed 2026-08-06 | |
| 2023-12-31 | $30.00K 10-K · filed 2025-03-31 | |
| 2022-12-31 | $27.00K 10-K · filed 2024-03-08 | |
| 2022-03-31 | $27.00K 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $87.00K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $76.00K 10-Q · filed 2022-11-04 | |
| 2021-03-31 | $10.00K 10-Q · filed 2022-11-04 | |
| 2020-12-31 | $58.00K 10-K · filed 2022-03-24 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $77.50K 10-K · filed 2019-03-07 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $708.62K 10-K · filed 2018-03-09 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $808.62K derived: sum of 4 quarters · filed 2017-02-24 |
| 2015-06-30 | $3.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $808.62K derived: sum of 4 quarters · filed 2017-02-24 |
| 2015-03-31 | $705.54K 10-Q · filed 2015-05-08 | $994.50K derived: sum of 4 quarters · filed 2017-02-24 |
| 2014-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | $358.95K 10-K · filed 2017-02-24 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | |
| 2014-06-30 | $188.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-13 | |
| 2014-03-31 | $70.00K 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $90.00K 10-K · filed 2016-03-14 | |
| 2011-12-31 | $59.24K 10-K · filed 2014-03-21 | |
| 2010-12-31 | $107.24K 10-K · filed 2014-03-21 | |
| 2009-12-31 | $3.60K 10-K · filed 2014-03-21 | |
| 2008-12-31 | $31.20K 10-K · filed 2014-03-21 | |
| 2007-12-31 | $60.00K 10-K · filed 2014-03-21 | |
| 2006-12-31 | $14.81K 10-K · filed 2014-03-21 | |
| 2005-12-31 | $9.60K 10-K · filed 2014-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |